Jerusalem, 3 June, 2025 (TPS-IL) — Israeli biotech company KAHR Bio announced positive results from a Phase 2 study of its drug DSP107 combined with atezolizumab for advanced colorectal cancer. The treatment helped patients live longer and showed strong activity against tumors, including in those with hard-to-treat liver metastases.

DSP107, developed in Modiin, Israel, works by activating the immune system to fight cancer. Patients receiving the combination lived a median of 17 months, compared to 8.1 months with DSP107 alone. The treatment was well tolerated, with no serious side effects. KAHR plans further studies to confirm these promising results and will share more data next year on lung cancer treatment.

TPS

See Full Bio